-

09:46:38 PM

ORMP Stock News

ORMP - Oramed Pharmaceuticals, Inc

11/29/22 8:40 AM

Nasdaq : ORMP

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original

RHEA-AI

neutral

11/17/22 12:26 PM

Nasdaq : ORMP

clinical trial

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. Key opinion leaders' discussion highlights new data and

RHEA-AI

neutral

11/14/22 7:55 AM

Nasdaq : ORMP

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

RHEA-AI

very positive

11/10/22 4:30 PM

Nasdaq : ORMP

earnings

Oramed Reports Third Quarter 2022 Financial Results

Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter

RHEA-AI

very positive

11/09/22 8:40 AM

Nasdaq : ORMP

conferencesclinical trial

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company

RHEA-AI

neutral

10/07/22 8:40 AM

Nasdaq : ORMP

clinical trialcovid-19

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

RHEA-AI

neutral

09/13/22 8:40 AM

Nasdaq : ORMP

clinical trial

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

RHEA-AI

neutral

09/06/22 7:55 AM

Nasdaq : ORMP

conferences

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person

RHEA-AI

neutral

07/26/22 7:55 AM

Nasdaq : ORMP

clinical trial

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com), a

RHEA-AI

neutral

07/11/22 7:55 AM

Nasdaq : ORMP

conferences

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ORMP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.oramed.com
CeoNadav Kidron
Security nameOramed Pharmaceuticals, Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1185 Avenue Of The Americas, 3Rd Floor
StateNew York
CityNew York
Zip10036
CountryUS
Phone16468441164

About Oramed Pharmaceuticals, Inc

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.